ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 84 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $21,049,699 | -9.0% | 3,479,289 | +16.8% | 0.04% | -5.0% |
Q2 2023 | $23,119,283 | +69.1% | 2,979,289 | +24.2% | 0.04% | +33.3% |
Q1 2023 | $13,675,737 | -3.2% | 2,399,252 | 0.0% | 0.03% | -45.5% |
Q4 2022 | $14,131,594 | +109.6% | 2,399,252 | +13.9% | 0.06% | +150.0% |
Q3 2022 | $6,742,000 | -28.6% | 2,106,968 | 0.0% | 0.02% | -12.0% |
Q2 2022 | $9,439,000 | -7.3% | 2,106,968 | +10.5% | 0.02% | +25.0% |
Q1 2022 | $10,183,000 | -51.5% | 1,906,968 | +33.6% | 0.02% | -48.7% |
Q4 2021 | $20,977,000 | +0.6% | 1,426,968 | +43.1% | 0.04% | +11.4% |
Q3 2021 | $20,847,000 | +18.2% | 996,989 | 0.0% | 0.04% | +34.6% |
Q2 2021 | $17,637,000 | -27.9% | 996,989 | -0.1% | 0.03% | -27.8% |
Q1 2021 | $24,452,000 | -19.6% | 998,061 | +11.1% | 0.04% | -26.5% |
Q4 2020 | $30,399,000 | +301.1% | 898,061 | +196.3% | 0.05% | +250.0% |
Q3 2020 | $7,579,000 | – | 303,061 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $4,673,631 | 14.75% |
Nextech Invest Ltd. | 4,285,714 | $33,257,141 | 11.30% |
Column Group LLC | 3,568,181 | $27,689,085 | 10.75% |
Prosight Management, LP | 5,522,936 | $42,857,984 | 6.42% |
Invus Financial Advisors, LLC | 1,007,575 | $7,818,782 | 4.18% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,450,822 | $11,258,379 | 3.48% |
VR Adviser, LLC | 2,142,856 | $16,628,563 | 2.66% |
Euclidean Capital LLC | 747,550 | $5,800,988 | 1.49% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $16,628,555 | 0.99% |
Monaco Asset Management SAM | 378,222 | $2,935,003 | 0.82% |